PRP, platelet-rich plasma
Calcium ions play an essential role in initiating or terminating cellular functions by mechanisms that either involve the influx platelets, Ca2+ content can be described as a three-compartment mace. a surface comDonent. and two intracellular comDonents.
. . one rapidly exchangeable with external Ca2+ and the ;her vir; tually nonexchangeable. The nonexchangeable space represents Ca2+ sequestered in su~cellular storage &anules, and alteration of Ca" binding and/or.fluxes in the other compartments has an important role in the process of platelet aggregation and exocytosis (I). In subjects with Down's syndrome, blood platelets have decreased Na+/Kt-ATPase activity and increased intracellular Na+ (9) . In erythrocytes, it has been reported that Na+/K+-ATPase is inhibited by increases in intracellular Ca2+ (2, 3), which mav lead to raised intracellular Na+ (13): thus. it seemed pertinent to determine the Ca2+ content of blood platelets from subjects with Down's syndrome as a possible factor contributing to decreased Na+/K+-ATPase activity. England Nuclear. LaC12 was spectrographic grade from Fisher Chemicals. All other chemicals were from commercial sources and were the purest available.
Culcizlm determinution. Blood samples were collected by a siliconized Vacutainer with EDTA anticoagulant. The erythrocytes were sedimented at 100 x g for 20 min, and PRP was transferred to a plastic tube and recentrifuged at 150 X g for 10 min to remove contaminating white cells. Platelets were separated from plasma at 100 x g for 20 min, and after decanting the plasma, the platelet pellet was gently resuspended in buffer (150 mM NaC1, 1.0 mM EDTA, 0.35% albumin, pH 6.9, with NaOH), and the platelets were harvested by centrifugation at 700 x g for 10 min. All centrifugations took place at room temperature. The final platelet pellet was resuspended in lanthanum buffer (150 mM NaCI, 20 mM Tris-maleate, 0.35% albumin, 0.2% LaC13, pH 6.4), transferred to an acid-washed glass beaker, and ashed at 450°C for 18 h. The ashed residue was dissolved in deionized water containing HCI, and Ca" concentration was determined by atomic absorption spectrophotometry. For each platelet sample, calcium standards and lanthanum blanks were run in parallel.
Culcizrtn trunsport. Platelets separated from PRP by centrifugation were resuspended in imidazole-buffered saline (150 mM NaCI, 20 mM imidazole, 10 mM glucose, 2.5 mM MgC12, 0.05 mM ATP, 2.5 mM CaCI,, 0.5% albumin) to a final platelet concentration of 2 x 10-"latelets/ml.
After 5-min preincubation at 36"C, 5 pCi 45Ca'+ were added and the incubation continued for a further 90 min with gentle agitation. 45Ca2+ uptake was stopped by adding 4 ml ice-cold imidazole buffer followed by centrifugation. The platelet pellet was washed twice with ice-cold buffer and dissolved in 1 ml of 1% Triton X-100. 0.5-ml aliquots were taken for scintillation counting. Platelets in PRP or buffers were measured on a Coulter counter. Down's subjects were young adults of both sexes living at home. Controls were laboratory staff matched for sex and age. Informed consent was obtained from individuals, parents, or guardians.
RESULTS
The data from individual subjects for total platelet Ca2+ (nanomoles Ca"/ lo-' platelets) are given in Table 1 Table 2) .
DISCUSSION
The Ca" content of the human blood platelet exists in a number of intracellular "pools" with different rates of turnover (I), and although our values for Ca" concentration in normal platelets are similar to published values (l6), the reduction found in Down's syndrome platelets could be due to metabolic disturbances in any, or all, of the Ca" pools. Calcium is loosely bound to the platelet surface where it is freely exchangeable with extracellular Ca" and removable by chelating agents (I 7). As there is little difference between 45Ca" binding between normal or Down's platelets following short incubation times (data not given), it is unlikely that alterations in the surface binding of Ca" can explain the decreased levels in Down's syndrome. Approximately 80-90% ofthe total platelet Ca" is associated with the dense bodies (14) , complexed with adenine nucleotides and serotonin (4, 18) , and only slowly exchanges with extragranular Ca2+. As subjects with Down's syndrome exhibit decreased transport and storage of serotonin (7, 8) . a decrease in the number of serotonin storage granules could account for the low intracellular Ca", While this report was in preparation, More cJ1 ul. (10) reported that Down's platelets have a reduced number and volume of electron-dense bodies and that whole cell and dense body calcium levels are lower than normal, complementing our observations.
In addition to decreased Ca2+ content, our results also demonstrate decreased accumulation of 45Ca'+ in Down's platelets, but whether this represents decreased Ca" transport operating at the level of the plasma membrane, or sequestering of Ca" by the dense tubular system (12), is at present under investigation. It is of interest that the Ca" system in the human platelet membrane appears analogous to that in synaptic membranes (5, 6) where the common requirements for Ca" are seen in receptorbinding transmitter release membrane pump for Ca", and supports the use of the platelet for a peripheral model for the synaptosome (15) . Further studies on Ca" metabolism may provide additional understanding of Down's syndrome at a molecular level.
FPF, false positive fraction FEP, free erythrocyte protoporphyrin SF, serum ferritin TS, transferrin saturation A wide range of laboratory tests is currently used to assess systemic iron status in man. However, normal biological variability, measurement error, and confounding factors such as intercurrent infection may adversely affect the diagnostic efficiency of these tests. Some of these problems are minimized when iron status is operationally defined by the degree of hematologic response to iron administration. In assessing an individual's iron status, a significant rise in circulating hemoglobin mass in response to iron treatment provides reliable evidence of antecedent iron deficiency. Hemoglobin response can also be used to monitor the diagnostic efficiency of other tests of systemic iron status.
The evaluation of a test's diagnostic efficiency requires assessment of its discriminative capacity in circumstances where the frequency and nature of its diagnostic errors can be unequivocally determined. A test's accuracy (ratio of correct decisions to total number of subjects tested) is of limited usefulness as a general index of diagnostic performance because it is strongly affected by disease prevalence (8) .
If a test is to be used to discriminate iron-replete from irondepleted subjects, some definitive diagnostic criterion is needed to allow evaluation of that test. In k'igure 1, the performance of a hypothetical diagnostic test is examined. Diseased subjects, whose test result places them at the right of the cut-off point, a, will be FNs; normal individuals whose result is to the left of a will be FPs. The number of FPs can be reduced or eliminated by moving the cut-off a toward 6, to the lower end ofthe distribution for N. However. as a result of eliminating FPs, the FN fraction will be increased. Likewise. the number of FNs can be eliminated by moving the cut-off u to c, the upper end of the distribution for D. The cut-off point can be positioned so as to maximize a test's diagnostic performance in a given clinical or epidemiologic context (8) 
